BIO 2019 Notebook: Sharpless On Pricing, Takeda M&A Strategy, FDA Cell And Gene Therapy Staffing
Executive Summary
News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout; and CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates.
You may also be interested in...
Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
BIO 2019 Notebook: Merck On Finding The Right Balance, Sandoz On The Next Wave Of Biosimilars, NORD On Patient Engagement
News and views from day three of the BIO International Convention: Merck’s Frazier champions both social justice and capitalism; Sandoz’s Pike thinks refinement of clinical data requirements will encourage biosimilar sponsors to target more moderate-selling biologics; National Organization for Rare Disorders’ Salstonstall sees impact from FDA reviewers talking to patients.
BIO 2019 Notebook: Merck; Out-Licensing Deals; RMAT
News and views from day one of the BIO International Convention: Merck reaffirms commitment to antibiotic space the same day Zerbaxa picks up a new indication; BIO survey finds out-licensing cash for emerging firms more than doubled in 2018; US FDA regenerative medicine advanced therapy designations now outnumber breakthrough designations for cell/gene therapies.